CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Immtech Pharmaceuticals, Inc. is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Immtech Pharmaceuticals, Inc.
One North End Avenue
Phone: (212) 791-2911p:212 791-2911 New York, NY  10282  United States Fax: (212) 791-2917f:212 791-2917
On 1/21/2014, the U.S. Securities and Exchange Commission revoked the registration of each class of registered securities of Immtech Pharmaceuticals, Inc. failure to make required periodic filings with the Commission.
This company is no longer actively traded on any major stock exchange.
Business Summary
Immtech Pharmaceuticals, Inc. is focused on global opportunities in the healthcare sector and other opportunities in China, including in the mining industry. The Company focuses on developing a new treatment for the Hepatitis C virus (HCV). The Company’s subsidiaries include Immtech Hong Kong Limited, Immtech Therapeutics Limited, Super Insight Limited and Immtech Life Science Limited. On September 22, 2008, the Company incorporated Gold Avenue Ltd. (Gold Avenue). Gold Avenue was established as an investment holding company with a focus on investing in metal and mineral assets in China.
(Source: 10-K)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
3/31/20093/31/2009YesYes---

Industries
SIC Code Description
2836 Biological products, except diagnostic substances
6719 Offices of holding companies, not elsewhere classified

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board, President, Chief Executive Officer Eric L.Sorkin 51 5/1/2006 1/6/2000
Vice Chairman of the Board CeciliaChan 47 11/13/2007 7/1/1999
Chief Financial Officer, Secretary, Treasurer Gary C.Parks 59
4 additional Officers and Directors records available in full report.

Business Names
Business Name
Immtech Hong Kong Limited
Immtech Pharmaceuticals, Inc.
Immtech Therapeutics Limited
Super Insight Limited

General Information
Number of Employees: 11 (As of 6/30/2009)
Outstanding Shares: 17,806,586 (As of 7/10/2009)
Shareholders: 2,576
Stock Exchange: OTC
Federal Tax Id: 391523370
Fax Number: (212) 791-2917
Email Address: info@immtechpharma.com


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Friday, July 21, 2023